Covid-19
Study shows high effectiveness of the Pfizer mRNA COVID-19 vaccine in pregnancy.
7 Sep, 2021 | 21:48h | UTCEffectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy – Nature Medicine
Commentaries on Twitter
NEW: Estimated vaccine effectiveness in #pregnancy from 7 through to 56 d after second dose was 96% (95% CI; 89–100%) for any documented infection, 97% (91–100%) for infections with documented symptoms & 89% (43–100%) for #COVID19-related hospitalization. https://t.co/bm950wUWGL
— All Source Pregnancy (@PregnancyAll) September 7, 2021
The Pfizer-BioNTech mRNA COVID-19 vaccine was estimated to have high vaccine effectiveness in pregnant women, which is similar to the effectiveness estimated in the general population, according to a @NatureMedicine paper. https://t.co/oz5zn7zNdq pic.twitter.com/9IP5ocxzXs
— Nature Portfolio (@NaturePortfolio) September 7, 2021
[Preprint] M-A of 12.011.447 individuals finds individuals previously infected with SARS-CoV-2 had an 81% reduction in odds of a reinfection.
7 Sep, 2021 | 21:42h | UTC
Commentary on Twitter
A new systematic review of over 12 million people from 54 studies at up to 8 months following Covid. >90% prevalence of IgG antibodies, reinfection 0.2% (an 81% risk reduction) https://t.co/ljir4DV1zU ("did not examine evidence for immunity against the new variants") pic.twitter.com/pT7A2KA9FV
— Eric Topol (@EricTopol) September 7, 2021
AAP flu recommendations allow for coadministration with COVID-19 vaccine.
7 Sep, 2021 | 21:44h | UTCNews release: AAP flu recommendations allow for coadministration with COVID-19 vaccine – American Academy of Pediatrics
Technical report: Recommendations for Prevention and Control of Influenza in Children, 2021–2022 – American Academy of Pediatrics
Commentary on Twitter
The 2021-’22 @AmerAcadPeds flu policy emphasizes the importance of flu vaccination during the SARS-CoV-2 pandemic, allows for coadministration with COVID-19 vaccine. https://t.co/usLaO276Ku pic.twitter.com/EaL5vocxMm
— AAP News (@AAPNews) September 7, 2021
Extended intervals and extra doses of the AstraZeneca vaccine are associated with increased immunogenicity.
7 Sep, 2021 | 10:56h | UTCInvited commentary: Longer intervals and extra doses of ChAdOx1 nCoV-19 vaccine
Commentaries on Twitter
(thread – click for more)
Substudy suggests extended interval (up to 45 wks) before 2nd dose of ChAdOx1 nCoV-19 leads to increased antibody titres, offering more flexibility in vaccine schedules.
Extended interval before 3rd dose resulted in further increase in immune responses. https://t.co/J3xOwSSYMN pic.twitter.com/8GotDI4ctS
— The Lancet (@TheLancet) September 2, 2021
(thread – click for more)
New @TheLancet
The heightened immune response to longer spacing @AstraZeneca 1st -> 2nd vaccine doses and the response 3rd booster dose, with high neutralizing antibodies and T cellshttps://t.co/A2UcPVIFYP pic.twitter.com/zfYaW0T8Yf— Eric Topol (@EricTopol) September 1, 2021
[Preprint] Large cohort study in Brazil showed AstraZeneca vaccine had high overall effectiveness against severe disease to individuals up to 89 years of age. In comparison, CoronaVac had high overall effectiveness against severe disease in individuals up to 79 years.
7 Sep, 2021 | 10:54h | UTC
Annual Update in Intensive Care and Emergency Medicine 2021 – Covid articles.
7 Sep, 2021 | 10:50h | UTCSecondary infections in critically ill patients with COVID-19
Tracheostomy for COVID-19: evolving best practice
See also: Non-Covid articles
Case series: COVID-19 mRNA vaccination leading to CNS inflammation.
7 Sep, 2021 | 10:49h | UTCCOVID-19 mRNA vaccination leading to CNS inflammation: a case series – Journal of Neurology
Opinion | Video: Immunity is the only way through a pandemic (w/Dr. Monica Gandhi).
7 Sep, 2021 | 10:45h | UTCImmunity Is The Only Way Through A Pandemic (w/Dr. Monica Gandhi) – ZDoggMD
CDC report: Hospitalization rates for Covid-19 were 10 times higher among unvaccinated than among fully vaccinated adolescents.
7 Sep, 2021 | 10:52h | UTCCommentaries:
More kids hospitalized with Covid-19 in states with lower vaccination rates, CDC report finds – CNN
Child COVID hospital cases up in low-vaccination states – CIDRAP
Commentary on Twitter
From late June to mid-August, there was a 10x increase in the rate of hospitalizations among children ages 0-4 with #COVID19 while the #DeltaVariant was widely circulating. It is critical for children to #maskup and get vaccinated if eligible. Learn more: https://t.co/aHC1vYdKVG. pic.twitter.com/uUeNPG6d5r
— CDC (@CDCgov) September 3, 2021
[Not published yet] Sinovac booster shot reverses drop in antibody activities against Delta-study.
7 Sep, 2021 | 10:47h | UTCSinovac booster shot reverses drop in antibody activities against Delta-study – Reuters
Commentary on Twitter
A booster dose of Sinovac Biotech's COVID-19 vaccine reversed a decline in antibody activities against the Delta variant, a study showed, easing some concerns about its longer-term immune response to the highly contagious strain of the virus. https://t.co/QdmMYVBrvl
— Reuters Health (@Reuters_Health) September 6, 2021
More data showing increased risk of hospitalization with SARS-CoV-2 delta variant.
6 Sep, 2021 | 11:12h | UTCHospitalisation associated with SARS-CoV-2 delta variant in Denmark – The Lancet Infectious Diseases
The resurgence of SARS-CoV-2 infection in a highly vaccinated health system workforce; vaccine effectiveness against infection was reduced from above 90% from March through June to 65% in July.
6 Sep, 2021 | 11:09h | UTCRelated:
Another study shows Pfizer mRNA vaccine immunity is reduced over time.
Commentary on Twitter (thread – click for more)
💥 NEW DATA💥
1/ "Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce" published today in @NEJM details ↓ in vaccine effectiveness against INFECTION among @UCSDHealth employees – from 95%+ in the spring to 65% in July
👉🏽 https://t.co/wMgjoLgJzS pic.twitter.com/lgOwlEqUQG
— Christopher A. Longhurst, MD (@CALonghurst) September 1, 2021
RCT: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels.
6 Sep, 2021 | 11:11h | UTC
Commentary on Twitter
The SAVE-MORE phase 3 study demonstrates the efficacy of anakinra, an IL-1α/β inhibitor, in patients with COVID-19 and high serum levels of soluble plasminogen activator receptor, according to a @NatureMedicine paper. https://t.co/aM5teLMipK pic.twitter.com/bTVNqbBOcv
— Nature Portfolio (@NaturePortfolio) September 3, 2021
Large surveillance study finds severe adverse events after COVID-19 mRNA vaccination are rare.
6 Sep, 2021 | 11:02h | UTCSurveillance for Adverse Events After COVID-19 mRNA Vaccination – JAMA
Editorial: Safety Surveillance of COVID-19 mRNA Vaccines Through the Vaccine Safety Datalink – JAMA
Commentaries:
mRNA COVID vaccines not tied to serious side effects – CIDRAP
Researchers find no serious health effects linked to mRNA COVID-19 vaccines – News Medical
Commentary on Twitter
Concerned about the safety of mRNA vaccines? This study of 6.2 million people who got 11.8 million doses is immensely reassuring. https://t.co/nUIqTacl0g pic.twitter.com/JBvenRVrRc
— David Juurlink (@DavidJuurlink) September 4, 2021
Viewpoint | Strengthening global health security and reforming the international health regulations: making the world safer from future pandemics.
6 Sep, 2021 | 11:00h | UTC
Interactive infographic showing the effects of Delta: How coronavirus spreads through a population and how we can beat it.
6 Sep, 2021 | 10:59h | UTCHow coronavirus spreads through a population and how we can beat it – The Guardian
Infographic: Vaccine passports around the world.
3 Sep, 2021 | 10:27h | UTCVaccine passports around the world – The BMJ
Double vaccination halves risk of Long COVID.
3 Sep, 2021 | 10:29h | UTCNews release: Double vaccination halves risk of Long COVID – King’s College London
Commentaries:
Largest study of its kind finds face masks reduce COVID-19 – University of California – Berkeley
Study: Vaccines slash long-haul COVID, hospital rates – CIDRAP
Vaccination reduces risk of long Covid, even when people are infected, U.K. study indicates – STAT
Being fully vaccinated reduces odds of long-term Covid-19 symptoms by half, UK study suggests – CNN
Coronavirus vaccines cut risk of long Covid, study finds – BBC
Related: M-A: More than 50 long-term effects of COVID-19.
Commentary on Twitter
NEW evidence on breakthrough infections indicates people who tested positive for #SARS-CoV-2 after 1 or 2 vaccine doses had significantly lower odds of severe disease, hospitalisation, or #LongCOVID than unvaccinated. https://t.co/MgHt7Ztqa0 @TheLancetInfDis pic.twitter.com/nt2b7jVrH9
— The Lancet (@TheLancet) September 1, 2021
WHO says it is monitoring a new Covid variant called ‘mu’.
3 Sep, 2021 | 10:21h | UTCWHO says it is monitoring a new Covid variant called ‘mu’ – CNBC
See also:
What’s the Mu variant? And will we keep seeing more concerning variants? – The Conversation
WHO monitoring new coronavirus variant named ‘Mu’ – France 24
New ‘mu’ coronavirus variant could escape vaccine-induced immunity, WHO says – LiveScience
WHO monitoring new coronavirus variant named Mu – The Guardian
[Preprint] Largest study of masks yet details their importance in fighting Covid-19.
3 Sep, 2021 | 10:30h | UTCLargest study of masks yet details their importance in fighting Covid-19 – NBC News
Original study: The Impact of Community Masking on COVID-19: A Cluster-Randomized Trial in Bangladesh – Innovations for Poverty Action
See also: A Study In Bangladesh Tripled The Rate Of Mask-Wearing. Can It Help In The U.S.? – NPR
Commentaries on Twitter (thread – click for more)
This is arguably the most important single piece of epidemiological research of the entire pandemic.
A MASSIVE randomized trial launched a pro-mask campaign in some Bangladeshi villages, but not others.
The result: masking villages got less COVID. https://t.co/8uKPXAvvnU
— Lyman Stone 石來民 🦬🦬🦬 (@lymanstoneky) September 1, 2021
(thread from the author – click for more)
Some misinterpretation of our #Bangladesh Mask RCT by those who don’t read research, which I’ll ignore, but also some parochial/racist reactions, which I must respond to https://t.co/FFeqz1zox5
— Mushfiq Mobarak (@mushfiq_econ) September 2, 2021
EU agency says to focus on vaccines first not booster shots.
3 Sep, 2021 | 10:34h | UTCEU agency says to focus on vaccines first not booster shots – Associated Press
See also: European officials say COVID-19 booster isn’t urgent – CIDRAP
Opinion | “The downsides of masking young students are real”.
3 Sep, 2021 | 10:24h | UTCThe Downsides of Masking Young Students Are Real – The Atlantic
Commentary with a rebuttal on Twitter (thread – click for more)
I'm not greatly interested in the school/mask debate, but I must say this is pretty wild – the article leads with this statement and then proceeds to offer no evidence whatsoever of any harms except "subjective [sic] shortness of breath" https://t.co/JL1Iadt8fy pic.twitter.com/5bZmvOhWo7
— Health Nerd (@GidMK) September 2, 2021
Reimagining construction and renovation of health care facilities during emergence from a pandemic.
3 Sep, 2021 | 10:19h | UTC
RCT: Baricitinib reduced mortality in hospitalized adults with COVID-19.
2 Sep, 2021 | 10:17h | UTCCommentaries:
Commentaries on Twitter
NEW—Baricitinib did not improve the composite primary endpoint of progression to NIV,
high-flow O2, IMV, or death; however, it did reduce 28-day all-cause mortality by 38·2% vs placebo (HR 0·57 [95% CI 0·41–0·78])Read the COV-BARRIER study: https://t.co/QrU6GW0XcQ#ISICEM2021
— The Lancet Respiratory Medicine (@LancetRespirMed) September 1, 2021
(thread – click for more)
1/🧵💥 NEW COVID THERAPY SAVES LIVES
Adding baricitinib to steroids will save 1,000s of hospitalized #COVID pts. Our @LancetRespirMed COV-Barrier study is FREE.
I explain👇why it’s such a great #Pandemic discovery story: a new way to ⬇️ COVID19 deaths.https://t.co/8I5BlwyT2R pic.twitter.com/6KcfQrljqC
— WesElyMD (@WesElyMD) September 1, 2021
Review | COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses.
2 Sep, 2021 | 10:06h | UTC
Commentary on Twitter
NEW REVIEW—COVID-19 and immune-mediated inflammatory diseases
Filippo Fagni and colleagues @UniFAU review the effect of disease and treatment on #COVID19 outcomes and #vaccine responseshttps://t.co/ue8XnDF1sM #LancetRheumatology @KorayTascilar pic.twitter.com/Yrk4SmeSbE
— The Lancet Rheumatology (@TheLancetRheum) August 27, 2021


